PXS 5382A

Drug Profile

PXS 5382A

Alternative Names: PXS-5382A

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmaxis
  • Class Pyrans; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors; Protein-lysine 6-oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pulmonary fibrosis
  • Preclinical Cancer; Hepatic fibrosis; Non-alcoholic steatohepatitis; Renal fibrosis

Most Recent Events

  • 30 Oct 2017 Phase-I clinical trials in Pulmonary fibrosis (In volunteers) in Australia (PO) (ACTRN12617001564347)
  • 12 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in Australia (PO), before October 2017 (ACTRN12617001564347)
  • 06 Sep 2017 Preclinical trials in Renal fibrosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top